| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 201.66 | 8.0% | 11.2% |
| Total Income | 201.66 | 8.0% | 11.2% |
| Expenditure | 211.43 | 3.2% | 7.7% |
| PBT | 1.83 | 110.4% | 104.0% |
| Net Profit | 2.24 | 113.1% | 105.0% |
| OPM | -4.84% | 4.93pp | 21.42pp |
| NPM | 1.11% | 10.27pp | 25.98pp |
| EPS | — |
NeoGenomics Reports Q2 2026 Results, Revenue Up 11% YoY to $202 Million
29 Jul 2026 · 29 Jul, 1:42 am
Summary
NeoGenomics reported a strong second quarter of 2026 with total revenue up 11% year-over-year to $202 million, driven by robust growth in clinical services and NGS testing. Adjusted EBITDA saw a significant 36% increase to $14 million, reflecting disciplined margin expansion. The company also generated $20 million from operations and raised its full-year 2026 guidance for both revenue and adjusted EBITDA, indicating confidence in continued profitable growth.
Key Highlights
- 1
Total revenue increased 11% year-over-year to $202 million for the second quarter of 2026.
- 2
Clinical services revenue grew 14% to $187 million, driven by a 26% increase in NGS revenue.
- 3
The company recorded GAAP net income of $2 million for the quarter, which included an $11 million gain on extinguishment of debt.
- 4
Adjusted EBITDA increased by 36% to $14 million, compared to $11 million in the prior year's second quarter.
- 5
Cash from operations generated $20 million, and the company ended the quarter with $146 million in cash, cash equivalents, and short-term investments.
- 6
NeoGenomics is raising its full-year 2026 revenue and adjusted EBITDA guidance.
Management Comments
Tony Zook
Our second quarter results reflect the consistent operating and financial performance investors expect from this team. Revenue growth of 11% year-over-year exceeded our outlook, with NGS revenue growth of 26% reflecting a continued mix shift to more advanced testing modalities. This revenue growth is being coupled with our focus on disciplined margin expansion, as evidenced by adjusted EBITDA increasing by 36%. Looking ahead, I remain confident that we are well positioned to deliver long-term profitable growth, while investing in our business and expanding our suite of on-market testing solutions for patients and providers.
Informational and educational content only. Not investment advice.